89bio, Inc.
NASDAQ:ETNB
7.94 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | 89bio, Inc. |
Symbool | ETNB |
Munteenheid | USD |
Prijs | 7.94 |
Beurswaarde | 933,601,080 |
Dividendpercentage | 0% |
52-weken bereik | 6.43 - 16.63 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Rohan Palekar |
Website | https://www.89bio.com |
An error occurred while fetching data.
Over 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)